Oncolytics Biotech (TSE:ONC) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncolytics Biotech has announced the commencement of a new study phase for pelareorep in combination with mFOLFIRINOX, and potentially atezolizumab, to treat metastatic pancreatic cancer, supported by a significant PanCAN award. The company aims to expand treatment options and improve outcomes for patients with this aggressive cancer. The study is a notable step in Oncolytics Biotech’s plan to develop pelareorep as a cornerstone immunotherapy for various cancers.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.